ID   HCmel1274
AC   CVCL_B0CF
SY   Melanoma model 3; M3
DR   ATCC; CRL-3475
DR   GEO; GSM4301284
DR   Wikidata; Q108820427
RX   PubMed=32284588;
CC   Doubling time: ~16-20 hours (ATCC=CRL-3475).
CC   Transformant: ChEBI; CHEBI_254496; 7,12-dimethyltetraphene (DMBA; dimethylbenzanthracene).
CC   Omics: Genomics; Whole exome sequencing.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Breed/subspecies: C57BL/6 Cdk4R24C/R24C, Hgftg.
DI   NCIt; C21790; Mouse melanoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
SX   Female
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 10-04-25; Version: 8
//
RX   PubMed=32284588; DOI=10.1038/s41591-020-0818-3; PMCID=PMC8482620;
RA   Perez-Guijarro E., Yang H.H., Araya R.E., El Meskini R., Michael H.T.,
RA   Vodnala S.K., Marie K.L., Smith C., Chin S., Lam K.C., Thorkelsson A.,
RA   Iacovelli A.J., Kulaga A., Fon A.-Y., Michalowski A.M., Hugo W.,
RA   Lo R.S., Restifo N.P., Sharan S.K., Van Dyke T., Goldszmid R.S.,
RA   Ohler Z.W., Lee M.P., Day C.-P., Merlino G.T.;
RT   "Multimodel preclinical platform predicts clinical response of
RT   melanoma to immunotherapy.";
RL   Nat. Med. 26:781-791(2020).
//